Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7806881
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Small Molecules
01
Overview
RO7806881 is an investigational new molecular entity (NME) being developed by Hoffmann-La Roche. As of early 2026, the compound is in Phase 1 clinical development, with a primary study (NCT07271693) evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The trial is a first-in-human, randomized, placebo-controlled study utilizing single and multiple ascending dose (SAD/MAD) cohorts. While the specific biological target, mechanism of action, and intended therapeutic indications for RO7806881 have not yet been publicly disclosed by the developer, its progression into clinical trials marks its transition from preclinical research into human evaluation.
Beyond the preview
Go deeper on RO7806881.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7806881.